Evaxion Reports Positive Preclinical Data for AML Vaccine EVX-04
EVAX sits 76% above its 52-week low of $2.07 on light trading volume (0.3× avg).
Summary
Evaxion announced strong preclinical results for its EVX-04 vaccine candidate for acute myeloid leukemia, showing successful immune activation and targeted cell-killing.
Key Events · Product Development and Regulatory · EVAX
-
Positive Preclinical Data for EVX-04
New data shows EVX-04, an off-the-shelf AML vaccine, is successfully expressed and secreted in human cells, enabling immune recognition and activation.
-
Targeted Immune Response
EVX-04 antigens drive specific immune responses in both mice and human cells, inducing targeted cell-killing across different immune profiles.
-
Presentation at EHA 2026 Congress
The detailed preclinical data will be presented at the European Hematology Association (EHA) 2026 Congress on June 13, 2026.
-
Advancing Towards Clinical Testing
The company is preparing the regulatory filing for clinical testing of EVX-04, which targets non-conventional endogenous retrovirus (ERV) tumor antigens.
Analysis · EVAX · Life Sciences
This filing details positive preclinical data for Evaxion's off-the-shelf acute myeloid leukemia (AML) vaccine candidate, EVX-04. The data demonstrates successful expression, immune activation, and targeted cell-killing, supporting its potential as a new therapeutic option for AML patients. This advances the program towards regulatory filing for clinical testing.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.6M. The 52-week trading range was $2.07 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.